Morgan Stanley’s Upstream Bio UPB Stock Holding History
Bought
Maintained
Sold
Other funds holding UPB
Morgan Stanley's UPB Position: Q3 2026 in Review
Morgan Stanley increased its Upstream Bio (UPB) stake by 21% in Q3 2026, buying an estimated $728K and bringing the position to 635,905 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4544.
Morgan Stanley first reported a position in UPB in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.97M in Q1 2026. 135 funds tracked by Wall St. Rank hold UPB as of Q3 2026.
- Morgan Stanley held 635,905 shares of Upstream Bio worth $3.35M as of Q3 2026.
- Morgan Stanley bought 111,273 Upstream Bio shares in Q3 2026, an estimated $728K.
- Upstream Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #4544 holding.
- Morgan Stanley first reported a position in Upstream Bio in Q4 2024 and has held it in 8 quarters since.
- Morgan Stanley's Upstream Bio position peaked at $4.97M in Q1 2026.
- 135 funds tracked by Wall St. Rank held Upstream Bio as of Q3 2026.
Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.